DGIdb - BEVACIZUMAB Drug Record

BEVACIZUMAB chembl:CHEMBL1201583 ApprovedAntineoplasticImmunotherapy

Alternate Names:

RHUMAB-
R-435
FKB-238
12-IGG1
BS-503A
HLX-04
BEVACIZUMAB
BEVACIZUMAB BETA
RHUMAB-VEGF
BI 695502
RG-435
AVASTIN
AVA-1
HLX04
ANTIVEGF
drugbank:00112
chembl:CHEMBL1201583
chemidplus:216974-75-3
pubchem.compound:135329020
rxcui:253337

Drug Info:

FDA Approval	approved
Drug Class	monoclonal antibody
Drug Indications	antineoplastic agent
FDA Approval	Cervical cancer, colorectal cancer, fallopian tube cancer, glioblastoma, non-small cell lung cancer, ovarian cancer, peritoneal cancer, renal cell carcinoma
Drug Class	Therapeutic Antibodies
Year of Approval	2004
Drug Class	antineoplastic agents

(8 More Sources)

Publications:

Park UC et al., 2014, Genetic factors associated with response to intravitreal ranibizumab in Korean patients with neovascular age-related macular degeneration., Retina
Chang W et al., 2013, Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population., Mol Vis
Hagstrom SA et al., 2013, Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT)., Ophthalmology
Tian J et al., 2012, Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population., Pharmacogenomics
Gampenrieder SP et al., 2017, Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer., Pharmacogenomics J
Hein A et al., 2015, Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study., Int J Cancer
Wang L et al., 2015, Association between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-Analysis., PLoS One
Miyake M et al., 2014, Vascular endothelial growth factor gene and the response to anti-vascular endothelial growth factor treatment for choroidal neovascularization in high myopia., Ophthalmology
Abedi F et al., 2013, Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration., Ophthalmology
Hansen TF et al., 2011, The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer., Pharmacogenomics J
Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics
Gerber et al., 2005, Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies., Cancer Res.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Sathornsumetee S et al., 2008, Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan., J Clin Oncol
Han K et al., 2016, Population pharmacokinetics of bevacizumab in cancer patients with external validation., Cancer Chemother Pharmacol
Janku et al., 2011, PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors., Mol. Cancer Ther.
Souglakos J et al., 2009, Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer., Br J Cancer
Yang et al., 2012, Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer., Cancer Res.
Tol J et al., 2009, BRAF mutation in metastatic colorectal cancer., N Engl J Med
Matsusaka S et al., 2017, CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy., Pharmacogenomics J
Hanker et al., 2013, Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies., Proc. Natl. Acad. Sci. U.S.A.
Basho et al., 2017, Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab., JAMA Oncol
Falchook et al., 2015, Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors., Invest New Drugs
Rini et al., 2006, Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status., BJU Int.
Yamasaki et al., 2012, Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy., Cancer Sci.
Budai B et al., 2012, Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab., Pharmacogenet Genomics
Li M et al., 2018, Identification of a Genomic Region between <i>SLC29A1</i> and <i>HSP90AB1</i> Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)., Clin Cancer Res
Said et al., 2013, P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy., Oncotarget
Wheler et al., 2016, TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics., Mol. Cancer Ther.
Hochster, 2006, Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer., Semin. Oncol.
Pander J et al., 2015, Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer., PLoS One
Jubb et al., 2006, Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer., J. Clin. Oncol.
Erdem-Eraslan et al., 2016, Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial., Cancer Res.
Tabouret et al., 2016, MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study., Oncotarget
Pérez-Ramírez C et al., 2019, Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients., Pharmacogenomics J
Chen JS et al., 2010, A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma., Anticancer Drugs
Smit EF et al., 2009, Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer., J Clin Oncol
Berger MD et al., 2018, A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab., Clin Cancer Res
Rosell et al., 2017, Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial., Lancet Respir Med
Petrelli et al., 2013, KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials., Med. Oncol.
Venook et al., 2017, Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial., JAMA
Volz NB et al., 2015, Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer., Pharmacogenomics J
Kwak et al., 2015, Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer., Cancer Discov
Hautamäki A et al., 2013, Interleukin 8 promoter polymorphism predicts the initial response to bevacizumab treatment for exudative age-related macular degeneration., Retina
Ince et al., 2005, Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab., J. Natl. Cancer Inst.
Piao et al., 2016, Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models., Neuro-oncology
Medina FM et al., 2015, Pharmacogenetic Effect of Complement Factor H Gene Polymorphism in Response to the Initial Intravitreal Injection of Bevacizumab for Wet Age-Related Macular Degeneration., Ophthalmic Res
Chen G et al., 2015, Pharmacogenetics of Complement Factor H Y402H Polymorphism and Treatment of Neovascular AMD with Anti-VEGF Agents: A Meta-Analysis., Sci Rep
Lotery AJ et al., 2013, Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study., Ophthalmology
Kang HK et al., 2012, Pharmacogenetic influence of LOC387715/HTRA1 on the efficacy of bevacizumab treatment for age-related macular degeneration in a Korean population., Korean J Ophthalmol
Smailhodzic D et al., 2012, Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration., Ophthalmology

BEVACIZUMAB CFH

Interaction Score: 7.31

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26439641 26411831 24070809 23842101 23584701 23559864 23337555 23204795 22840423 22594510

Sources:
PharmGKB
BEVACIZUMAB HTRA1

Interaction Score: 4.99

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23842101 23559864 23337555 22594510

Sources:
PharmGKB
BEVACIZUMAB THBS2

Interaction Score: 3.99

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16365183

Sources:
NCI
BEVACIZUMAB ARMS2

Interaction Score: 3.99

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22594510

Sources:
PharmGKB
BEVACIZUMAB VEGFB

Interaction Score: 1.5

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20124951

Sources:
ClearityFoundationClinicalTrial PharmGKB
BEVACIZUMAB VEGFA

Interaction Score: 1.05

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name Avastin

Novel drug target Established target

Notes

PMIDs:
27139155 26100253 25955730 23953100 23149126 20125120 20124951 15705858 11752352 18182667 27329360

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TEND CIViC PharmGKB TTD
BEVACIZUMAB RGS5

Interaction Score: 1.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25069475

Sources:
PharmGKB
BEVACIZUMAB MGAT4A

Interaction Score: 1.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26222057

Sources:
PharmGKB
BEVACIZUMAB VEGFC

Interaction Score: 1.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20124951

Sources:
ClearityFoundationClinicalTrial PharmGKB
BEVACIZUMAB SHMT1

Interaction Score: 0.8

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22044939

Sources:
PharmGKB
BEVACIZUMAB GC

Interaction Score: 0.57

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29208668

Sources:
PharmGKB
BEVACIZUMAB GGH

Interaction Score: 0.4

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
BEVACIZUMAB VHL

Interaction Score: 0.4

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type renal cell carcinoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
16827904 22931246

Sources:
JAX-CKB
BEVACIZUMAB EDN1

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27139155

Sources:
PharmGKB
BEVACIZUMAB MMP9

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26921265

Sources:
CIViC
BEVACIZUMAB MTHFR

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29662106 20634689 19307503

Sources:
PharmGKB
BEVACIZUMAB PRKCA

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29871907

Sources:
PharmGKB
BEVACIZUMAB CXCR4

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27503580

Sources:
PharmGKB
BEVACIZUMAB MMP2

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26921265

Sources:
CIViC
BEVACIZUMAB BRAF

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Bevacizumab + Temsirolimus + Doxil

Indication/Tumor Type ovarian carcinoma

Response Type sensitive

PMIDs:
21216929 19603024 22180495 19571295

Sources:
JAX-CKB CIViC
BEVACIZUMAB HRAS

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15998951

Sources:
NCI
BEVACIZUMAB HSP90AB1

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29871907

Sources:
PharmGKB
BEVACIZUMAB KRAS

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Bevacizumab + Sorafenib

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
23828442 21216929 28632865 25363205

Sources:
JAX-CKB CIViC
BEVACIZUMAB MET

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Altiratinib + Bevacizumab

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
25363205 26432108 26965451

Sources:
JAX-CKB
BEVACIZUMAB CXCL8

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23584701

Sources:
PharmGKB
BEVACIZUMAB PIK3CA

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type resistant

Approval Status Preclinical

Indication/Tumor Type Her2-receptor positive breast cancer

PMIDs:
23940356 27893038 21216929 25363205

Sources:
JAX-CKB
BEVACIZUMAB KIT

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Bevacizumab + Sorafenib

Indication/Tumor Type gastrointestinal stromal tumor

Response Type sensitive

PMIDs:
25363205

Sources:
JAX-CKB
BEVACIZUMAB ERBB2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BKM120 + Bevacizumab

Indication/Tumor Type Her2-receptor positive breast cancer

Response Type sensitive

PMIDs:
26432108 23940356

Sources:
JAX-CKB
BEVACIZUMAB EGFR

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Bevacizumab + Erlotinib

Indication/Tumor Type lung adenocarcinoma

Response Type sensitive

PMIDs:
28408243

Sources:
JAX-CKB
BEVACIZUMAB TP53

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type sensitive

Approval Status Phase III

PMIDs:
23670029 27466356 17145525

Sources:
JAX-CKB
BEVACIZUMAB IDH1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Bevacizumab + Lomustine

Indication/Tumor Type glioblastoma multiforme

Response Type predicted – sensitive

PMIDs:
26762204

Sources:
JAX-CKB

TEND: BEVACIZUMAB
- Version: 01-August-2011
Alternate Names:

BEVACIZUMAB Primary Drug Name

Drug Info:

Drug Class antineoplastic agents

Year of Approval 2004

Publications:

MyCancerGenome: BEVACIZUMAB

Version: 20-Jun-2017

Alternate Names:

BEVACIZUMAB Generic Name

AVASTIN Trade Name

Drug Info:

Drug Class Therapeutic Antibodies

FDA Approval Cervical cancer, colorectal cancer, fallopian tube cancer, glioblastoma, non-small cell lung cancer, ovarian cancer, peritoneal cancer, renal cell carcinoma

Publications:

TdgClinicalTrial: BEVACIZUMAB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class monoclonal antibody

FDA Approval approved

Publications:

NCI: BEVACIZUMAB

Version: 14-September-2017

Alternate Names:

C2039 NCI drug code

Drug Info:

Publications:

Jubb et al., 2006, Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer., J. Clin. Oncol.

Ince et al., 2005, Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab., J. Natl. Cancer Inst.

JAX-CKB: Bevacizumab

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Janku et al., 2011, PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors., Mol. Cancer Ther.

Rini et al., 2006, Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status., BJU Int.

Yamasaki et al., 2012, Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy., Cancer Sci.

PharmGKB: bevacizumab

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Tian J et al., 2012, Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population., Pharmacogenomics

Chang W et al., 2013, Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population., Mol Vis

Park UC et al., 2014, Genetic factors associated with response to intravitreal ranibizumab in Korean patients with neovascular age-related macular degeneration., Retina

CIViC: BEVACIZUMAB

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Tol J et al., 2009, BRAF mutation in metastatic colorectal cancer., N Engl J Med

Souglakos J et al., 2009, Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer., Br J Cancer

Yang et al., 2012, Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer., Cancer Res.

TALC: BEVACIZUMAB
- Version: 12-May-2016
Alternate Names:

BEVACIZUMAB Primary Drug Name

BEVACIZUMAB Drug Generic Name

AVASTIN Drug Trade Name

Drug Info:

Publications:
TTD: Bevacizumab
- Version: 2020.06.01
Alternate Names:

D04KBL TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1201583
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1201583
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: BEVACIZUMAB
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:

Indication/Tumor Type	renal cell carcinoma
Response Type	sensitive
Approval Status	Preclinical

combination therapy	Bevacizumab + Temsirolimus + Doxil
Indication/Tumor Type	ovarian carcinoma
Response Type	sensitive

combination therapy	Bevacizumab + Sorafenib
Indication/Tumor Type	colorectal cancer
Response Type	sensitive

combination therapy	Altiratinib + Bevacizumab
Indication/Tumor Type	glioblastoma multiforme
Response Type	sensitive

Response Type	resistant
Approval Status	Preclinical
Indication/Tumor Type	Her2-receptor positive breast cancer

combination therapy	BKM120 + Bevacizumab
Indication/Tumor Type	Her2-receptor positive breast cancer
Response Type	sensitive

combination therapy	Bevacizumab + Erlotinib
Indication/Tumor Type	lung adenocarcinoma
Response Type	sensitive

combination therapy	Bevacizumab + Lomustine
Indication/Tumor Type	glioblastoma multiforme
Response Type	predicted – sensitive

BEVACIZUMAB	Primary Drug Name
BEVACIZUMAB	Drug Generic Name
AVASTIN	Drug Trade Name

antibody (inhibitory)
inhibitor (inhibitory)

BEVACIZUMAB Drug Record

BEVACIZUMAB chembl:CHEMBL1201583 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26439641 26411831 24070809 23842101 23584701 23559864 23337555 23204795 22840423 22594510

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23842101 23559864 23337555 22594510

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16365183

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22594510

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20124951

Sources: ClearityFoundationClinicalTrial PharmGKB

Interaction Types & Directionality: antibody (inhibitory) inhibitor (inhibitory)

Interaction Info: Trial Name Avastin Novel drug target Established target Notes

PMIDs: 27139155 26100253 25955730 23953100 23149126 20125120 20124951 15705858 11752352 18182667 27329360

Sources: TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TEND CIViC PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25069475

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26222057

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20124951

Sources: ClearityFoundationClinicalTrial PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22044939

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29208668

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type renal cell carcinoma Response Type sensitive Approval Status Preclinical

PMIDs: 16827904 22931246

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27139155

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26921265

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29662106 20634689 19307503

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29871907

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27503580

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26921265

Interaction Types & Directionality:

n/a

PMIDs:
26439641 26411831 24070809 23842101 23584701 23559864 23337555 23204795 22840423 22594510

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23842101 23559864 23337555 22594510

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16365183

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
22594510

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20124951

Sources:
ClearityFoundationClinicalTrial PharmGKB

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name Avastin

Novel drug target Established target

Notes

PMIDs:
27139155 26100253 25955730 23953100 23149126 20125120 20124951 15705858 11752352 18182667 27329360

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TEND CIViC PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
25069475

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26222057

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20124951

Sources:
ClearityFoundationClinicalTrial PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22044939

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29208668

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type renal cell carcinoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
16827904 22931246

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
27139155

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26921265

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
29662106 20634689 19307503

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29871907

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27503580

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26921265

Sources:
CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Bevacizumab + Temsirolimus + Doxil

Indication/Tumor Type ovarian carcinoma

Response Type sensitive

PMIDs:
21216929 19603024 22180495 19571295

Sources:
JAX-CKB CIViC

Interaction Types & Directionality:

n/a

PMIDs:
15998951

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
29871907

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Bevacizumab + Sorafenib

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
23828442 21216929 28632865 25363205

Sources:
JAX-CKB CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Altiratinib + Bevacizumab

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
25363205 26432108 26965451

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
23584701

Sources:
PharmGKB